China Securities Intelligent Finance News: CStone Pharmaceuticals-B (02616) announced on the morning of November 7th that it will present its pipeline drug CS2015 (OX40L/TSLP bispecific antibody) in the field of autoimmune and inflammation for the first time at the 2025 American Academy of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting through electronic posters and oral presentations. This will be the drug's first appearance at an international academic conference.
　　According to the announcement, CS2015 employs an asymmetric molecular structure, simultaneously targeting two key inflammatory regulators, OX40L and TSLP, and utilizes a mutant Fc to prolong its circulating half-life, supporting long-term dosing intervals. Preclinical studies have shown that this molecule can potently inhibit inflammatory signaling pathways, exhibiting rapid reduction in skin lesions, decreased immune cell infiltration, and relief of itching in animal models of atopic dermatitis.
　　The announcement indicates that, in terms of drug metabolism, CS2015 exhibits excellent pharmacokinetic characteristics in non-human primates, with an average half-life of 21 days (subcutaneous injection) and 25.7 days (intravenous injection). Simultaneously, the drug possesses excellent drug-like properties, including high-temperature stability, low viscosity suitable for high-concentration subcutaneous injection, and has shown potent therapeutic effects in asthma models.
　　CStone Pharmaceuticals will further develop CS2015 for the treatment of Th2 cell-mediated inflammatory diseases such as atopic dermatitis, asthma, and hidradenitis suppurativa.
　　CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research and development of drugs for oncology, autoimmune diseases, and inflammation. The company has successfully launched four innovative drugs .It has obtained approval for 16 new drug applications and currently has 16 drug candidates in its R&D pipeline.

https://finance.eastmoney.com/a/202511073557979523.html